Literature DB >> 15388280

A 5-HT(2C) receptor-mediated interaction between 2,5-dimethoxy-4-methylamphetamine and citalopram in the rat.

J R Eckler1, C J Reissig, R A Rabin, J C Winter.   

Abstract

Previous studies conducted in our laboratory have shown that acute administration of the selective serotonin re-uptake inhibitor (SSRI), citalopram, potentiates the stimulus effects of the phenethylamine hallucinogen [-]-2,5-dimethoxy-4-methylamphetamine (DOM) in the rat while neither substituting for the DOM stimulus when administered alone nor altering brain levels of DOM. The present investigation was designed to determine the mechanism by which citalopram acts on DOM-induced stimulus control. To that end, we tested the following hypotheses: (a) citalopram blocks the transport of DOM by the serotonin transporter, (b) citalopram acts via the 5-HT(1A) receptor, and (c) citalopram acts via the 5-HT(2C) receptor. Hypothesis (a) was rejected on the basis of equilibrium saturation studies of [3H]citalopram binding, which revealed no significant affinity of DOM for the 5-HT transporter of rat brain membranes. Hypotheses (b) and (c) were tested in a group of 20 rats in which stimulus control was established with DOM (0.6 mg/kg; 75 min pretreatment time). A two-lever, fixed ratio 10 (FR10), positively reinforced task with saline controls was employed. Hypothesis (b), a role for the 5-HT(1A) receptor, was rejected on the basis of an absence of antagonism of the effects of citalopram on DOM by the selective 5-HT(1A) receptor antagonist, WAY-100635. In contrast, Hypothesis (c), a role for the 5-HT(2C) receptor, gained support from the observation of significant antagonism of the effects of citalopram on DOM by the selective 5-HT(2C) receptor antagonist, SB-242084.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388280     DOI: 10.1016/j.pbb.2004.06.012

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Effects of serotonin (5-HT)1A and 5-HT2A receptor agonists on schedule-controlled responding in rats: drug combination studies.

Authors:  Jun-Xu Li; Caroline Crocker; Wouter Koek; Kenner C Rice; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2010-12-21       Impact factor: 4.530

3.  Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.

Authors:  J C Winter; J R Eckler; K C Rice; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2005-07       Impact factor: 3.533

4.  Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas.

Authors:  M M Doat-Meyerhoefer; R Hard; J C Winter; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2005-08       Impact factor: 3.533

5.  Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.

Authors:  J C Winter
Journal:  Psychopharmacology (Berl)       Date:  2008-11-01       Impact factor: 4.530

6.  Psilocybin-induced stimulus control in the rat.

Authors:  J C Winter; K C Rice; D J Amorosi; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2007-06-22       Impact factor: 3.533

7.  Marked decrease of LSD-induced stimulus control in serotonin transporter knockout mice.

Authors:  C M Krall; J B Richards; R A Rabin; J C Winter
Journal:  Pharmacol Biochem Behav       Date:  2007-09-14       Impact factor: 3.533

8.  5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice.

Authors:  Adam L Halberstadt; Iris van der Heijden; Michael A Ruderman; Victoria B Risbrough; Jay A Gingrich; Mark A Geyer; Susan B Powell
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.